Urban Clouds

Newsroom

Press Releases

Since
Sep 22, 2022

Please visit News and Press Releases at FSD Pharma, for items since Sep 22, 2021.

Sep 22, 2021 

FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today it has retained the services of Hybrid Financial Ltd. (“Hybrid”), North Equities Corp. (the "North Equities"), Looking Glass Capital Consultants (“Looking Glass”), Worldwide Media Solutions, LLC (“BGTV Direct”), KCSA Strategic Communications ("KCSA"), and Digi Messaging & Advertising (“Digi”)...

Sep 21, 2021 

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of the previously announced acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. (“Lucid”)...

Aug 25, 2021 

FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, announces today it has entered a definitive agreement to acquire 100% of the issued and outstanding shares Lucid Psycheceuticals Inc. (“Lucid”)...

June 14, 2021 

Lucid Psycheceuticals Announces Exclusive License to Develop Cutting-Edge Neurodegenerative Disease Therapeutics

Lucid Psycheceuticals Inc. (Lucid), a psychedelics-inspired company focusing on total brain health, today announced that it has entered into a world-wide license agreement with University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications in neurodegenerative disorders.

In The News

In The News

Since
Sep 22, 2021

Please visit News and Press Releases at FSD Pharma, for items since Sep 22, 2021.

In The News

Aug 18, 2021 

Lucid Psycheceuticals focusing on Total Brain Health

Leonard Zehr August 17, 2021, BIOTUESDAYS

Closely-held Lucid Psycheceuticals’ next generation approach to total brain health is targeting the interface between mental health and neurodegenerative disorders with therapeutic products inspired by psychedelics and new chemical entities.